
Medirom Healthcare (MRM) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Income Metrics
Balance Sheet Metrics
Total Assets
54.8M
Total Liabilities
46.7M
Shareholders Equity
8.0M
Debt to Equity
5.81
Cash Flow Metrics
Revenue & Profitability Trend
Medirom Healthcare Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 56.2M | 46.2M | 47.1M | 5.4B | 3.3B |
Cost of Goods Sold | 41.0M | 35.6M | 34.2M | 4.0B | 2.9B |
Gross Profit | 15.2M | 10.6M | 12.9M | 1.4B | 429.0M |
Gross Margin % | 27.1% | 23.0% | 27.4% | 26.2% | 12.8% |
Operating Expenses | |||||
Research & Development | - | - | - | - | - |
Selling, General & Administrative | 15.2M | 13.3M | 12.2M | 1.8B | 1.1B |
Other Operating Expenses | -93.8K | -144.8K | -139.7K | -27.8M | -111.6M |
Total Operating Expenses | 15.1M | 13.1M | 12.1M | 1.8B | 957.0M |
Operating Income | 126.1K | -2.5M | 796.4K | -379.5M | -528.0M |
Operating Margin % | 0.2% | -5.4% | 1.7% | -7.0% | -15.8% |
Non-Operating Items | |||||
Interest Income | 54 | 7.5K | 41.1K | 839.0K | 1.3M |
Interest Expense | 336.9K | 249.7K | 66.4K | 12.0M | 13.2M |
Other Non-Operating Income | 533.9K | 2.9M | 446.4K | -23.8M | -86.8M |
Pre-tax Income | 323.1K | 139.7K | 1.2M | -414.5M | -626.7M |
Income Tax | -612.8K | -639.5K | 208.7K | 576.2M | -87.5M |
Effective Tax Rate % | -189.6% | -457.9% | 17.1% | 0.0% | 0.0% |
Net Income | 935.9K | 779.2K | 1.0M | -990.7M | -539.2M |
Net Margin % | 1.7% | 1.7% | 2.1% | -18.3% | -16.1% |
Key Metrics | |||||
EBITDA | 2.4M | -883.3K | 2.4M | -228.1M | -444.7M |
EPS (Basic) | - | $23.64 | $30.54 | $-203.13 | $-223.88 |
EPS (Diluted) | - | $22.34 | $27.23 | $-203.13 | $-223.88 |
Basic Shares Outstanding | - | 33067 | 33033 | 706823777 | 698867055 |
Diluted Shares Outstanding | - | 33067 | 33033 | 706823777 | 698867055 |
Income Statement Trend
Medirom Healthcare Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 2.2M | 720.3K | 4.1M | 370.6M | 1.4B |
Short-term Investments | 41.7K | 179.5K | 179.5K | 26.5M | 32.5M |
Accounts Receivable | 9.2M | 4.2M | 3.6M | 312.3M | 148.5M |
Inventory | 1.0M | 948.1K | 772.8K | 18.7M | 8.0M |
Other Current Assets | 1.5M | 1.7M | 2.0M | 111.2M | - |
Total Current Assets | 18.3M | 11.9M | 16.0M | 1.4B | 2.1B |
Non-Current Assets | |||||
Property, Plant & Equipment | 14.0M | 14.2M | 13.2M | 1.8B | 1.6B |
Goodwill | 13.0M | 12.8M | 10.0M | 1.6B | 399.1M |
Intangible Assets | 7.7M | 6.2M | 2.7M | 391.0M | 97.6M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 3.1M | 1.4M | 765.1K | 209.1M | 852.0M |
Total Non-Current Assets | 36.5M | 34.5M | 29.7M | 4.4B | 3.6B |
Total Assets | 54.8M | 46.4M | 45.7M | 5.8B | 5.7B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 6.9M | 932.6K | 1.4M | 230.9M | 67.0M |
Short-term Debt | 12.9M | 8.6M | 5.9M | 917.5M | 900.6M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 2.8M | 2.5M | 3.6M | 418.8M | 118.9M |
Total Current Liabilities | 28.3M | 24.1M | 24.7M | 3.2B | 2.7B |
Non-Current Liabilities | |||||
Long-term Debt | 13.9M | 16.2M | 16.0M | 1.9B | 1.7B |
Deferred Tax Liabilities | - | - | - | - | - |
Other Non-Current Liabilities | 1.7M | 1.8M | 2.3M | 354.1M | 383.2M |
Total Non-Current Liabilities | 18.4M | 20.8M | 21.4M | 2.8B | 2.6B |
Total Liabilities | 46.7M | 44.9M | 46.1M | 6.0B | 5.2B |
Equity | |||||
Common Stock | 2.4M | 135.5K | 8.3M | 1.2B | 1.2B |
Retained Earnings | 1.6M | 543.7K | -17.2M | -2.7B | -1.7B |
Treasury Stock | 20.3K | 20.3K | 20.3K | 3.0M | 3.0M |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 8.0M | 1.5M | -402.1K | -208.3M | 491.3M |
Key Metrics | |||||
Total Debt | 26.8M | 24.7M | 21.9M | 2.8B | 2.6B |
Working Capital | -10.0M | -12.2M | -8.7M | -1.8B | -565.4M |
Balance Sheet Composition
Medirom Healthcare Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 935.9K | 779.2K | 1.0M | -990.7M | -539.2M |
Depreciation & Amortization | 2.0M | 1.7M | 1.2M | 126.2M | 62.3M |
Stock-Based Compensation | - | 0 | 0 | 196.9M | 0 |
Working Capital Changes | 6.7M | 1.8M | -3.0M | -45.9M | -107.1M |
Operating Cash Flow | 8.7M | 3.9M | -728.2K | -161.3M | -689.4M |
Investing Activities | |||||
Capital Expenditures | -483.6K | -920.0K | -542.6K | -95.7M | -70.3M |
Acquisitions | 6.0M | 4.0M | 4.8M | 54.2M | -99.2M |
Investment Purchases | -38.3K | -21.0K | 0 | -78.9M | -26.7M |
Investment Sales | 200.2K | 0 | 0 | 6.0M | 63.0M |
Investing Cash Flow | 5.8M | 3.1M | 4.2M | -65.8M | -109.0M |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | - | - | - | - | - |
Debt Issuance | 2.0M | 0 | 3.7M | 0 | 775.0M |
Debt Repayment | -4.6M | -671.1K | -1.4M | -251.1M | -386.4M |
Financing Cash Flow | 4.1M | 3.1M | 1.2M | -515.6M | 1.2B |
Free Cash Flow | -12.8M | -10.5M | -5.8M | -671.0M | -470.5M |
Net Change in Cash | 18.6M | 10.1M | 4.7M | -742.7M | 447.0M |
Cash Flow Trend
Medirom Healthcare Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
9.47
Price to Book
0.02
Price to Sales
0.00
Profitability Ratios
Profit Margin
1.79%
Operating Margin
13.30%
Return on Equity
22.96%
Return on Assets
0.04%
Financial Health
Current Ratio
0.65
Debt to Equity
400.54
Beta
0.88
Per Share Data
EPS (TTM)
$0.19
Book Value per Share
$118.11
Revenue per Share
$1,624.92
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
mrm | 14.2M | 9.47 | 0.02 | 22.96% | 1.79% | 400.54 |
Rollins | 28.1B | 57.37 | 19.45 | 36.52% | 13.71% | 66.99 |
Service | 11.3B | 21.94 | 6.89 | 32.72% | 12.58% | 292.19 |
Medifast | 155.5M | 42.88 | 0.67 | 1.73% | 0.76% | 6.05 |
Yy Group Holding | 75.9M | 20.23 | 11.12 | -93.74% | -11.77% | 81.32 |
Regis | 47.7M | 0.52 | 0.69 | 548.07% | 49.34% | 535.95 |
Financial data is updated regularly. All figures are in the company's reporting currency.